CROI 2015 Program and Abstracts

Poster Listings

645 Effectiveness of Sofosbuvir/Simeprevir for HIV/HCV Patients in Clinical Practice Jody Gilmore 1 ; Kenneth Lynn 1 ; Delisha Breen 1 ; StaceyTrooskin 2 ; Jihad Slim 3 ; Nancy Scangarello 3 ; Alvin Kingcade 4 ; Katie Hunyh 4 ;Vincent Lo Re 1 ; Jay R. Kostman 1 1 Perelman School of Medicine, Philadelphia, PA, US; 2 Drexel University College of Medicine, Philadelphia, PA, US; 3 St Michael’s Medical Center, Newark, NJ, US; 4 Philadelphia Health Management Corporation, Philadelphia, PA, US 646 German Cohort on Sofosbuvir-Based Therapy for HIV/HCV and HCV Infection (GECOSO) Stefan Christensen 2 ; Ingiliz Patrick 3 ; Dietrich Hueppe 7 ;Thomas Lutz 4 ; Karl Georg Simon 6 ; Knud Schewe 5 ; Heiner Busch 2 ; Axel Baumgarten 3 ; Guenther Schmutz 1 ; Stefan Mauss 1 1 Center for HIV and Hepatogastroenterology, Duesseldorf, Germany; 2 CIM Infectious Diseases, Muenster, Germany; 3 Medizinisches Infektiologie Zentrum Berlin, Berlin, Germany; 4 Infektiologikum, Frankfurt, Germany; 5 Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany; 6 Practice for Gastroenterology Leverkusen, Leverkusen, Germany; 7 Practice for Gastroenterology Herne, Herne, Germany 647 Real-World Data on HIV-Positive Patients With HCV TreatedWith Sofosbuvir and/or Simeprevir David Del Bello 1 ; Kian Bichoupan 1 ; Calley Levine 1 ; Agnes Cha 2 ; David Perlman 1 ; Nadim H. Salomon 1 ; Donald Kotler 1 ; Daniel Fierer 1 ; Douglas Dieterich 1 ; Andrea Branch 1 1 Mount Sinai Health System, New York City, NY, US; 2 Brooklyn Medical Center, New York City, NY, US 648 Simeprevir and Sofosbuvir Regimens for Hepatitis C: Decompensation and Serious AEs Ponni V. Perumalswami 1 ; Kian Bichoupan 1 ; Lawrence Ku 1 ; Neal M. Patel 1 ; Rachana Yalamanchili 1 ;Thomas Schiano 1 ; MarkWoodward 2 ; Douglas Dieterich 1 ; Andrea D. Branch 1 1 Icahn School of Medicine at Mount Sinai, New York, NY, US; 2 George Institute for Health at the University of Oxford, Oxford, United Kingdom 649 Successful HCV Treatment With Direct Acting Antivirals in HIV/HCV Patients Jennifer L. Grant 1 ;Valentina Stosor 1 ; Frank J. Palella 1 ; Richard M. Green 1 ; GuajiraThomas 1 ; DonnaV. McGregor 1 ; Milena M. McLaughlin 2 ; Sudhir Penugonda 1 ; Michael Angarone 1 ; Claudia Hawkins 1 1 Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2 Midwestern University, Chicago, IL, US 650 Sofosbuvir/Daclatasvir in HIV/HCV Co-infected Patients With Extensive Liver Fibrosis Alissa Naqvi ; Francine Guillouet de Salvador; Isabelle Perbost; Brigitte Dunais; Aline Joulié; Rodolphe Garraffo; Pascal Pugliese; Jacques Durant; Pierre Marie Roger; Eric Rosenthal Centre Hospitalier Universitaire de Nice, Nice, France 651 Majority of HIV/HCV Patients Need to Switch ART to Accommodate Simeprevir Rebecca Cope 1 ; Aaron Pickering 2 ;Thomas Glowa 1 ; Samantha Faulds 1 ; PeterVeldkamp 1 ; Ramakrishna Prasad 1 1 University of Pittsburgh, Pittsburgh, PA, US; 2 University of Maryland, Glen Burnie, MD, US Session P-N3 Poster Session Poster Hall 2:30 pm– 4:00 pm Treatment of HCV with DAAs: Short-Term Costs and Long-Term Benefits 652 Simeprevir/Sofosbuvir vs Triple Therapy (Telaprevir or Boceprevir) for HCV GT1: A cost analysis Jacob A. Langness 1 ; DavidTabano 2 ; SarahTise 3 ; Lindsay Pratt 3 ; Lauren Ayres 3 ; Amanda Wieland 3 ; Sonia Lin 1 ;Vahram Ghuschcyan 2 ; Kavita Nair 2 ; Greg Everson 3 1 University of Colorado, Arvada, CO, US; 2 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, US; 3 University of Colorado, Aurora, CO, US 653 SVR Durability: HCV Patients TreatedWith IFN-Free DAA Regimens Aurielle M. Thomas 1 ; Sarah Kattakuzhy 1 ; Sarah Jones 2 ; Anita Kohli 1 ;Wilson Eleanor 2 ; Angie Price 2 ; Rachel Silk 2 ; Zayani Sims 1 ; Anu Osinusi 3 ; Shyam Kottilil 3 1 The National Institutes of Health, Bethesda, MD, US; 2 Leidos Biomedical Research, Inc., Bethesda, MD, US; 3 Institute of Human Virology, University of Maryland, Baltimore, MD, US

654 Five–Year Risk of Late Relapse or ReinfectionWith Hepatitis C After Sustained Virological Response: Meta-analysis of 49 Studies in 8534 Patients AndrewM. Hill 1 ; Bryony Simmons 2 ; Jawaad Saleem 2 ; Graham Cooke 2 1 Chelsea and Westminster Hospital, London, United Kingdom; 2 St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom 655 Incidence of Extrahepatic Complications in HIV/HCV Patients Who Achieved SVR Sebastiano Leone 1 ; Mattia Prosperi 2 ; Silvia Costarelli 1 ; Francesco Castelli 3 ; Franco Maggiolo 4 ; Simona Di Giambenedetto 5 ; Annalisa Saracino 6 ; Massimo Di Pietro 7 ; Fabio Zacchi 8 ; Andrea Gori 1 1 “San Gerardo Hospital”, University of Milano-Bicocca, Monza, Italy; 2 University of Manchester, Manchester, United Kingdom; 3 University of Brescia, Brescia, Italy; 4 Ospedali Riuniti, Bergamo, Italy; 5 Policlinico Gemelli, Rome, Italy; 6 Policlinico of Bari, Bari, Italy; 7 S.M Annunziata Hospital, Firenze, Italy; 8 Istituti Ospeitalieri di Cremona, Cremona, Italy 656 Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV JanetTate 1 ; E. JohnWherry 2 ; Jay R. Kostman 2 ; Debika Bhattacharya 4 ; Guadalupe Garcia- Tsao 5 ; Cynthia Gibert 6 ; Joseph K. Lim 5 ; David Rimland 3 ; Amy Justice 1 ; Vincent Lo Re 2 Veterans Aging Cohort Study ProjectTeam 1 VA Connecticute Health System, West Haven, CT, US; 2 Univeristy of Pennsylvania, Philadelphia, PA, US; 3 Atlanta VA Healthcare System, Atlanta, GA, US; 4 VA Greater Los Angeles, Los Angeles, CA, US; 5 Yale University School of Medicine, New Haven, CT, US; 6 Washington DC VA Medical Center, Washington, DC, US 657 Portal Pressure Changes After HCV Eradication in HIV/HCV+ Patients With Cirrhosis Matilde Sánchez-Conde; Leire Pérez-Latorre; Diego Rincón; Pilar Miralles; MaríaVega 2:30 pm– 4:00 pm HCV: Getting the Drugs to ThoseWho Need Them 658 Assessment of PCP Knowledge of HCV Screening, Recommendations, and Treatment Options Allison Brodsky ; Monique Allen; Gregory Johnson; Lora Magaldi; Carolyn Moy; NancyTursi; StephanieTzarnas; StaceyTrooskin Drexel University College of Medicine, Philadelphia, PA, US 659 Majority of HCV/HIV-Infected Patients in the Netherlands Remain in Need of Effective HCV Treatment Colette Smit 1 ; Joop E. Arends 2 ; Marc van derValk 3 ; Kees Brinkman 4 ; Heidi Ammerlaan 5 ; S. Arend 6 ; Peter Reiss 1 ; Clemens Richter 7 1 Stichting HIV Monitoring, Amsterdam, Netherlands; 2 Universitair Medisch Centrum Utrecht, Utrecht, Netherlands; 3 Academic Medical Center, Amsterdam, Netherlands; 4 Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; 5 CZE, Eindhoven, Netherlands; 6 Leiden University Medical Center, Leiden, Netherlands; 7 Rijnstate Ziekenhuis, Arnhem, Netherlands 660 Identifying and Prioritizing Hepatitis C Treatment for HIV-Hepatitis C Co-Infection Amanda D. Castel 1 ; Mariah M. Kalmin 1 ; Rachel Hart 2 ; Alan Greenberg 1 ; Henry Masur 3 DC Cohort Executive Committee 1 The Milken Institute School of Public Health at George Washington University, Washington, DC, US; 2 Cerner Corporation, Kansas City, MO, US; 3 National Institutes of Health (NIH), Bethesda, MD, US 661 One-Year Results of a Community-Based Hepatitis C Testing and Linkage- to-Care Program Christian B. Ramers 1 ; Robert Lewis 1 ; Letty Reyes 1 ; DanelleWallace 1 ; Robert Gish 3 ; David Wyles 2 ; Alex Kuo 1 1 Family Health Centers of San Diego, San Diego, CA, US; 2 University of California San Diego, La Jolla, CA, US; 3 Stanford University, Palo Alto, CA, US Catalina; Juan Carlos López; Rafael Bañares; Juan Berenguer Hospital General Universitario Gregorio Marañón, Madrid, Spain Session P-N4 Poster Session Poster Hall

Poster Listings

52

CROI 2015